Kailera Therapeutics, Inc.
KLRA
$14.70
-$0.15-0.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Net Income | -111.31M | -78.87M | -28.95M | ||
| Total Depreciation and Amortization | 101.00K | 101.00K | 62.00K | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | 6.96M | 2.99M | 1.31M | ||
| Change in Net Operating Assets | 26.72M | 7.47M | 1.35M | ||
| Cash from Operations | -77.53M | -68.31M | -26.23M | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -571.02M | 22.85M | -74.17M | ||
| Cash from Investing | -571.02M | 22.85M | -74.17M | ||
| Total Debt Issued | -- | -- | 100.00M | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | 668.87M | 57.00K | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -1.84M | -3.04M | -- | ||
| Cash from Financing | 667.03M | -2.98M | 100.00M | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 18.48M | -48.44M | -403.00K | ||